CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
22 hedge funds and large institutions have $7.52M invested in CASI Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
10% more funds holding
Funds holding: 20 → 22 (+2)
9.97% more ownership
Funds ownership: 9.87% → 19.84% (+10%)
8% less capital invested
Capital invested by funds: $8.14M → $7.52M (-$616K)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$328K |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$636 |
| 3 |
Morgan Stanley
New York
|
+$237 |
| 4 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$24 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$135K |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$87.8K |
| 3 |
WSC
Wellington Shields & Co
New York
|
-$61.7K |
| 4 |
WSCM
Wellington Shields Capital Management
New York
|
-$16K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$16K |
CASI Hedge Fund Activity: Q4 2024 in Review
22 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q4 2024, worth a combined $7.52M — down 7.6% from $8.14M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CASI positions and 2 closed out — a net gain of 2 holders — while 2 added to existing stakes and 6 trimmed.
The largest buyer was Woodline Partners, adding an estimated $328K. The largest seller was Citadel Advisors, exiting entirely with an estimated $135K sold.
- 22 institutional investors held CASI Pharmaceuticals (CASI) as of Q4 2024, up from 20 in Q3 2024.
- Funds reported $7.52M of CASI Pharmaceuticals stock for Q4 2024, down 7.6% quarter-over-quarter.
- 4 funds opened new CASI Pharmaceuticals positions in Q4 2024 and 2 closed out, a net change of +2 holders.
- The largest CASI Pharmaceuticals buyer in Q4 2024 was Woodline Partners, an estimated $328K added.
- The largest CASI Pharmaceuticals seller in Q4 2024 was Citadel Advisors, an estimated $135K sold.
Based on aggregated 13F filings for Q4 2024.